



## Effect of particle size on the biodistribution of lipid nanocapsules: Comparison between nuclear and fluorescence imaging and counting.

Samuli Hirsjärvi, Lucie Sancey, Sandrine Dufort, Camille Belloche, Claire Vanpouille-Box, Emmanuel Garcion, Jean-Luc Coll, François Hindré, Jean-Pierre Benoit

### ► To cite this version:

Samuli Hirsjärvi, Lucie Sancey, Sandrine Dufort, Camille Belloche, Claire Vanpouille-Box, et al.. Effect of particle size on the biodistribution of lipid nanocapsules: Comparison between nuclear and fluorescence imaging and counting.. International Journal of Pharmaceutics, 2013, 453 (2), pp.594-600. 10.1016/j.ijpharm.2013.05.057 . inserm-00855672

**HAL Id: inserm-00855672**

**<https://www.hal.inserm.fr/inserm-00855672>**

Submitted on 29 Aug 2013

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Effect of particle size on the biodistribution of lipid nanocapsules: comparison between nuclear and fluorescence imaging and counting

Samuli Hirsjärvi<sup>a,1,\*</sup>, Lucie Sancey<sup>b,c,1</sup>, Sandrine Dufort<sup>b</sup>, Camille Belloche<sup>a</sup>, Claire Vanpouille-  
5 Box<sup>a,d</sup>, Emmanuel Garcion<sup>a</sup>, Jean-Luc Coll<sup>b</sup>, François Hindré<sup>a</sup>, Jean-Pierre Benoît<sup>a</sup>

<sup>a</sup> LUNAM Université, Université d'Angers, INSERM U1066, Angers, France

<sup>b</sup> INSERM-UJF-CRI-U823, Institut Albert Bonniot, La Tronche, France

<sup>c</sup> UMR 5306 CNRS – Université Claude Bernard Lyon 1, Laboratoire de Physico-Chimie des  
10 Matériaux Luminescents, Villeurbanne, France

<sup>d</sup> Present affiliation: New York University School of Medicine, Department of Pathology, New  
York, NY, USA

<sup>1</sup> Equal contribution

15 \* *Corresponding author* (S. Hirsjärvi): [samuli.hirsjarvi@univ-angers.fr](mailto:samuli.hirsjarvi@univ-angers.fr), tel.: +33 2 44 68 85 45; fax:  
+33 2 44 68 85 46; address: INSERM U1066, IBS-CHU Angers, 4 rue Larrey, 49933 Angers,  
France.

## Abstract

20

*In vivo* biodistribution of nanoparticles depends on several physicochemical parameters such as size. After intravenous injection of 25, 50 and 100 nm lipid nanocapsules (LNC) in *nude* mice bearing HEK293( $\beta_3$ ) tumour xenografts, biodistribution was evaluated by  $\gamma$ -scintigraphy and by  $\gamma$ -counting. The small LNC 25 nm disappeared faster than the larger LNC 50 and 100 nm from the  
25 blood circulation due to faster elimination and wider tissue distribution. At 24 h, biodistribution profiles of all these LNC were similar. Low LNC quantities were found in this weak EPR (enhanced permeability and retention) tumour regardless the particle size. Co-injected 50 nm fluorescent DiD-LNC and  $^{99m}\text{Tc}$ -LNC allowed direct comparison of biodistribution as evaluated by the two methods. Optical imaging underestimated LNC quantity especially in dark-coloured organs  
30 that were observed to capture extensive quantities of the particles by  $\gamma$ -counting (*i.e.* liver, spleen, and kidney).

**Keywords:** lipid nanocapsules, biodistribution,  $\gamma$ -scintigraphy, optical imaging, fluorescence

## 35    **1 Introduction**

Extensive studying of nanoparticles during the last decades has resulted in drug delivery systems that protect the active substance, improve solubility and carry the drug to specific tissues in the body (Farokhzad and Langer, 2009). Cancer therapy is one of the areas that benefit considerably  
40 from these advances (Hirsjärvi et al., 2011). In order to develop an efficient nanoparticulate drug delivery system, its pharmacokinetic profile as well as biodistribution should be evaluated when the system is transferred from *in vitro* assays to first preclinical tests. Molecular imaging offers tools for non-invasive evaluation (Baker, 2010), and the same probes used also allow tissue distribution determination after animal sacrifice. Commonly used small animal imaging technologies include X-  
45 ray computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT) and different optical imaging techniques (Dufort et al., 2010). Optical imaging techniques are sensitive, non-ionizing, fast and easy to perform, portative and cheap. However, quantitative performance of optical techniques still needs improvement in order to overcome the problems of absorption and autofluorescence. SPECT  
50 can overcome optical imaging problems because it provides more reliable quantitative information about physiological functions at the molecular level and it is, thus, well suited for monitoring many vital processes such as blood flow and perfusion, receptor-ligand binding rates, and oxygen utilization. SPECT has no depth limit but the acquisition times might be from several minutes up to hours. However, SPECT suffers from some noteworthy other disadvantages such as the need of  
55 radiolabelled particles, and adapted and expensive devices. Both SPECT and optical imaging possess a resolution of 1 mm (for more detail, please see (Dufort et al., 2010)).

Biocompatible nanoparticles for drug delivery are usually made of polymer or lipid materials (Kumari et al., 2010; Müller et al., 2011; Torchilin, 2007; Torchilin, 2005). Lipid nanocapsules

60 (LNC) are synthetic particles having a hybrid structure between polymer nanoparticles and liposomes (Heurtault et al., 2002). LNC consist of low-toxicity materials (PEGylated surfactant, lecithin, triglycerides) and their fabrication, based on low-energy organic solvent-free phase inversion process, can be easily scaled up. By changing proportions of the components, the LNC size can be tuned within the range of 20-100 nm (Heurtault et al., 2003). LNC have been applied  
65 *e.g.* in the delivery of cancer therapeutics (Cirpanli et al., 2011; Garcion et al., 2006; Lacoeyille et al., 2007; Paillard et al., 2010; Peltier et al., 2006; Weyland et al., 2011) and other drug molecules (Lamprecht et al., 2004) as well as macromolecules such as siRNA and DNA (Morille et al., 2010; Morille et al., 2011). Because of their semi-rigid shell, LNC can be modified by post-inserting amphiphilic molecules. This kind of post-insertion allows for *e.g.* improvement of biodistribution  
70 profiles (Hoarau et al., 2004; Morille et al., 2010) or creation of templates for further attachment of active targeting ligands (Béduneau et al., 2008; Béduneau et al., 2007; Bourseau-Guilmain et al., 2012). Radioactive molecules such as  $^{99m}\text{Tc}$  and  $^{188}\text{Re}$  have been successfully encapsulated in LNC as forms of lipophilic complexes (Ballot et al., 2006). These kinds of radio-labelled LNC can be used in biodistribution studies, imaging purposes and in radiotherapy (Allard et al., 2008; Ballot et  
75 al., 2006; Vanpouille-Box et al., 2011a; Vanpouille-Box et al., 2011b).

In a previous study, we have evaluated the biodistribution profile of LNC of three different sizes (25, 50 and 100 nm) with the help of an optical imaging technique, fluorescence reflectance imaging (2D-FRI) (Hirsjärvi et al., 2013). *Nude* mice bearing subcutaneous HEK293( $\beta_3$ ) (human  
80 embryonic kidney) xenografts were used in the study. Images taken at 1.5-3 h after intravenous injection revealed that fluorescence staining of the smallest LNC (25 nm) was more homogeneous throughout the mice than the staining of the bigger LNC: the 50 and 100 nm LNC were found mostly in the liver. However, when the mice were sacrificed after 24 h, tissue distribution profiles,

evaluated by fluorescence intensity, were similar for the three LNC sizes. With all three sizes,  
85 tumour could be distinguished from the images.

In the present study, to get more quantitative information about LNC pharmacokinetics and  
biodistribution,  $^{99m}\text{Tc}$ -labelled LNC of the same three sizes (25, 50 and 100 nm) were injected  
intravenously in *nude* mice bearing the same tumour model (HEK293( $\beta_3$ ) xenografts).  $\gamma$ -  
90 Scintigraphy was performed at different time points up to 24 h together with tissue distribution  
determination by  $\gamma$ -counting at 1.5, 4 and 24 h. To compare the performance of 2D-FRI imaging  
(region of interest (ROI) drawing around each organ from the images taken with a fluorescence  
camera) and  $\gamma$ -counting in the determination of tissue distribution, mice were co-injected a mixture  
of fluorescence-labelled (DiD) and  $^{99m}\text{Tc}$ -labelled LNC of one chosen size (50 nm).

95

## 2 Materials and Methods

### 2.1 Materials

100 Solutol® HS15 (PEG 660 12-hydroxystearate,  $M_w \sim 870$  Da) (BASF, Ludwigshafen, Germany),  
Labrafac™ WL 1349 (caprylic/capric acid triglycerides) (Gattefossé S.A., Saint-Priest, France),  
Lipoid® S75-3 ( $M_w \sim 780$  Da) (Lipoid GmbH, Ludwigshafen, Germany), NaCl (Prolabo VWR  
International, Fontenay-sous-Bois, France) and deionized MilliQ185 water (Waters, Saint-Quentin-  
en-Yveline, France) were used in the LNC preparation. 1,1'-dioctadecyl-3,3,3',3'-  
105 tetramethylindodicarbocyanine perchlorate (DiD) was from Invitrogen (Cergy Pontoise, France).

## 2.2 Methods

110

### 2.2.1 Preparation of the $^{99m}\text{Tc}$ -SSS complex

115

120

Pertechnetate ( $^{99m}\text{TcO}_4^-$ ) was obtained from the University Hospital of Angers (CHU Angers, France). The  $^{99m}\text{Tc}$ -SSS complex (bis (perthiobenzoato) (dithiobenzoato) technetium(III) heterocomplex) was prepared according to the following method (Ballot et al., 2006; Mévellec et al., 2002): 750 MBq of  $^{99m}\text{TcO}_4^-$  in 0.5 mL 0.9% NaCl was added to a freeze-dried formulation kit containing 30 mg sodium gluconate, 30 mg ascorbic acid, 40 mg potassium oxalate, and 4 mg  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$  reconstituted in 0.5 mL 0.9% NaCl, and the solution was mixed for 15 minutes at room temperature. Then, 20 mg of sodium dithiobenzoate ligand (in 0.5 mL, pH 7) (Platform of Organic Synthesis, Rennes, France) was added and the mixture was heated at 100 °C for 30 minutes, which allowed formation of the  $^{99m}\text{Tc}$ -SSS complex. The complex was extracted with dichloromethane (1 mL) and washed three times with 1 mL water.

125

### 2.2.2 LNC preparation and characterization

130

LNC were prepared by the phase inversion temperature method described by Heurtault *et al.* (Heurtault et al., 2003). Solutol®, Lipoid®, Labrafac®, NaCl and water were mixed and the  $^{99m}\text{Tc}$ -SSS complex in dichloromethane ( $^{99m}\text{Tc}$ -LNC) or DiD in acetone (DiD-LNC) was added to this mixture. When preparing fluorescent LNC, final concentration of DiD was 3 mmol/L / total Labrafac® amount. Dichloromethane/acetone was evaporated by heating at 60 °C for 15 min under stirring. The formulation was heated to 85 °C at a rate of 5 °C / min followed by cooling at the same rate to 65 °C. This cycle was repeated twice. During the last decrease of temperature, at 78 °C (during the phase inversion zone), the system was diluted with 4.2 mL cold (4 °C) water leading to

formation of stable LNC. Size of the LNC (25, 50, 100 nm) was adjusted by changing the proportions of the components (Table 1).

Size distributions and zeta ( $\zeta$ ) potentials of LNC were determined with a Zetasizer ZS (Malvern, Worcestershire, UK). Particle sizing was based on photon correlation spectroscopy (PCS); the results were analyzed by CONTIN algorithm and the sizes were presented based on the volume distributions together with polydispersity indices (PdI). Electrophoretic mobilities were converted to  $\zeta$ -potentials using Smoluchowski's equation.

### 2.2.3 Cells

HEK293( $\beta_3$ ) cells, stable transfectants of human  $\beta_3$  from the human embryonic kidney cell line (kindly provided by J.-F. Gourvest, Aventis, France), were cultured in DMEM supplemented with 1% glutamine, 10% fetal bovine serum (FBS), 50 units/mL penicillin, 50  $\mu$ g/mL streptomycin, and 700  $\mu$ g/mL Geneticin (G418 sulfate, Gibco, Paisley, UK), at 37 °C in a humidified 95% air / 5% CO<sub>2</sub> atmosphere.

### 2.2.4 *In vivo* imaging and biodistribution study

The animal experiments were performed in agreement with the EU Directive 2010/63/EU for animal experiments, and the "Principles of Laboratory Animal Care" (NIH Publication no. 86-23, revised 1985), and the experimental protocol was approved by the local ethics committee.

40 female NMRI *nude* mice (5 weeks old, JANVIER, Le Genest Saint Isle, France) were injected subcutaneously with HEK293( $\beta_3$ ) cells ( $1 \times 10^7$  / mouse). After tumor growth (~ 4 weeks), mice



were anesthetized with a mixture of ketamine (100 µg/g) / medetomidine (0.2 µg/g) by an  
160 intraperitoneal injection, and then 200 µL of LNC (about 100 mg/mL) were injected intravenously  
in the tail vein. Thus, each mouse obtained a dose of about 26 MBq  $^{99m}\text{Tc}$  ( $^{99m}\text{Tc}$ -LNC). The mice  
which were injected by the mixture radio- and fluorescence-labelled LNC obtained 100 µL of  
 $^{99m}\text{Tc}$ -LNC (13 MBq) and 100 µL of DiD-LNC (same quantity of both LNC).

165 In  $\gamma$ -scintigraphy, the injected mice were visualized under a clinical  $\gamma$ -camera (Sopha Medical  
DSXi, 140 keV $\pm$ 15%, 128<sup>2</sup> matrix, HRLE collimator). Static 15 min scintigraphic images were  
registered at 1.5 h, 3 h, 5h, and 24 h (a video clip of dynamic 30 s scintigraphic acquisitions  
collected until 90 min post-injection is available as Supporting Content). To study tissue  
distribution of LNC, the animals were sacrificed at 1.5 h (n = 4), 4 h (n = 4), and 24 h (n = 4) after  
170 injection. The organs/tissues were removed, rinsed, and weighed. Activity of each removed organ  
was determined using a  $\gamma$ -counter (Packard Auto-Gamma 5,000 series).

Fluorescent images were acquired by a back-thinned CCD camera at -80°C (ORCAII-BT-512G,  
Hamamatsu, Massy, France). Image display and analysis of the dissected organs were performed  
175 using the Wasabi software (Hamamatsu, Massy, France). Semi-quantitative data were obtained by  
drawing regions of interest (ROI) around each organ. The results of organ fluorescence  
quantifications were expressed as number of relative light units (RLU)/pixel.

When imaging and quantifying the mice that obtained the mixture of radio- and fluorescence-  
180 labelled LNC, fluorescence acquisitions were performed before scintigraphic acquisitions and  $\gamma$ -  
counting.

### 2.2.5 Statistical analysis

185

Biodistribution data was analyzed using one-way ANOVA with Tukey's multiple comparison test (Prism, GraphPad Software, Inc., La Jolla, CA).  $p < 0.05$  was considered as statistically significant.

## 3 Results

190

### 3.1 LNC preparation

195

Size and  $\zeta$ -potential of  $^{99m}\text{Tc}$ -LNC are presented in Table 2. These characteristics of DiD-LNCs were identical with  $^{99m}\text{Tc}$ -LNC (Hirsjärvi et al., 2013). PdI-values of all three types of LNC were low indicating homogeneous size distributions. Slightly negative  $\zeta$ -potential of LNC originates from PEG groups at the surface forming dipoles able to interact with counterions or water dipoles (Vonarbourg et al., 2005). Encapsulation of lipophilic  $^{99m}\text{Tc}$  or DiD in the oily core of LNC did change neither size nor  $\zeta$ -potential of the blank LNC as reported earlier (Ballot et al., 2006; Morille et al., 2010; Paillard et al., 2010; Zou et al., 2008).

200

### 3.2 In vivo biodistribution of $^{99m}\text{Tc}$ -LNC

205

Biodistribution of 25, 50, and 100 nm  $^{99m}\text{Tc}$ -LNC in different organs 1.5 h, 4 h and 24 h after i.v. injections are presented in Figure 1. LNC 25 nm disappeared quickly from the blood circulation: 3-6% total CPM (counts per minute) / g of the 25 nm LNC was found in the blood at 1.5-4 h whereas the measured blood activities for LNC 50/100 nm were about 25-30 % at the same time points ( $p < 0.001$ : LNC 25 nm vs. LNC 50/100 nm). Conversely, at 24 h, total CPM / g of LNC 25 nm was higher (~3%) than the corresponding LNC 50/100 nm values (~1.5%;  $p < 0.01$ ). More activity of

LNC 25 nm was found in the liver at 1.5-4 h (~28%) compared to LNC 50 nm (16-18%;  $p < 0.01$ )  
 210 and LNC 100 nm (21-22%; difference not significant). Also, compared to LNC 50/100 nm, more  
 LNC 25 nm were found in the heart and in the lung ( $p < 0.01$ ), and in the adrenal at 1.5-4 h. In  
 contrast, at 24 h, less LNC 50 nm was found in the heart, lung and kidney compared to LNC 25/100  
 nm ( $p < 0.05$ ). The spleen captured less LNC 50 nm than LNC 25/100 nm at 1.5 h and 4 h ( $p <$   
 0.05). No significant differences were found in the tumour accumulation between the three particle  
 215 sizes at different time points (1-3% total CPM / g). Otherwise, distribution in other organs was  
 similar at different time points.

$\gamma$ -Scintigraphic images of mice 1.5 h, 3 h, 5 h, and 24 h after i.v. injection of 25, 50 and 100 nm  
 $^{99m}\text{Tc}$ -LNC are presented in Figure 2. The livers were well visible at 24 h. At earlier time points,  
 220 especially at 1.5 h and 3 h, more vertical highlighted regions revealed also radioactivity in the blood  
 circulation (heart, lungs). LNC 25 nm were better observable than LNC 50/100 nm in peripheral  
 regions and at intestinal area of mice at 3 h and 5 h. These observations were supported by the  $\gamma$ -  
 counting results: if the values “% CPM of all organs” were not corrected by the organ masses,  
 radioactivity in the carcass after the injection of LNC 25 nm were 39% at 1.5 h and 37% at 4 h.  
 225 Corresponding values for LNC 50 and 100 nm were 22% ( $p < 0.001$  vs. LNC 25 nm) and 22% ( $p <$   
 0.001); 15% ( $p < 0.01$ ) and 18% ( $p < 0.05$ ) at 1.5 h and 4 h, respectively. Also, at 4 h, 7.5% of LNC  
 25 nm were found in the intestine vs. 4.5% of LNC 50 nm and 3% of LNC 100 nm (both  $p < 0.01$   
 vs. LNC 25 nm).

### 230 3.3 Comparison of in vivo biodistribution of co-injected $^{99m}\text{Tc}$ -LNC and DiD-LNC

An example of fluorescence images of a mouse 24 h after injection of a 50%-50% mixture of 50 nm  
 DiD-LNC and  $^{99m}\text{Tc}$ -LNC is presented in Figure 3. Fluorescence staining allowed identifying of the

liver (A) and the tumour (B). LNC biodistribution in different organs at 24 h is presented in Figure 4. To better compare the quantification by the two techniques ( $\gamma$ -counting and fluorescence imaging), the organ data were normalized by the detected radioactivity (% ID/g) and fluorescence intensity (RLU/pixel/20 ms) in the bone. As already observed when testing radiolabelled LNC of different sizes, the majority of radioactivity was found in the liver as well as in the adrenal, spleen, and kidneys (Fig. 4A). Instead, the observed fluorescence intensity was also highest in the liver, but the next highest fluorescent organs were the ovaries, adrenal, and skin. The global fluorescence intensity in the spleen was low, and moderate in the kidneys. Radioactivity in relation to other organs was clearly higher in the liver, adrenal, spleen, kidney, ovary, and lung. No such clear differences were observed in fluorescence intensities. An image of the organs (Fig. 4B), used for the quantification, reveals well the highly fluorescent organs.

## 4 Discussion

Generally, sub-100 nm nanoparticles are expected to circulate longer time in the blood compared to > 100 nm particles (Vonarbourg et al., 2006). However, in the size range of 10-100 nm, surface and even elasticity properties of nanoparticles as well as their mechanism of elimination have been shown to dictate pharmacokinetic and biodistribution profiles. Also, animal model (mouse/rat) is known to affect tissue distribution (Sun et al., 2005). For example, systemic clearance and volume of distribution of 60 nm PEGylated polyacrylate nanoparticles in mice were significantly lower when compared to 20 nm particles, leading to lower liver uptake (~15% ID/g at 48 h) of the larger 60 nm particles (Yang et al., 2009). Similarly, 25 nm polymer micelles exhibited much shorter circulation half-lives than 60 nm micelles (2.2-fold decrease in the distribution phase  $t_{1/2}$ ) (Lee et al., 2010). More efficient clearance by hepatobiliary excretion of the smaller micelles was proposed as ~70% of the (mouse) liver fenestrations are narrower than 100 nm. The longest blood half-life of

10-100 nm PEGylated gold nanoparticles was achieved with ~60 nm particles by adjusting the size  
260 and PEG length (Perrault et al., 2009). On the other hand, mice plasma clearance rates (12% ID/mL  
plasma at 24 h), and the quantities in kidney (~4% ID/g), liver (10-16% ID/g) and in spleen (5-10%  
ID/g) were similar regardless of the polymer micelle size (30-100 nm) (Cabral et al., 2011). Several  
studies have proposed wider distribution, extravasation, of nanoparticles in different organs, the  
smaller the particle size was in the sub-100 nm range (De Jong et al., 2008; Hirn et al., 2011;  
265 Sonavane et al., 2008; Yang et al., 2009). Similarly to our results with 25, 50, and 100 nm LNC,  
shortened blood circulation time is frequently related to this wider biodistribution. Higher quantity  
of LNC 25 nm in the liver (1.5, 4 h) compared to LNC 50/100 nm in the current study indicated  
also faster hepatic accumulation. Radioactivity found in the kidneys can be explained by LNC  
accumulation. To undergo a complete renal clearance, the nanoparticle size should be less than 10  
270 nm (Choi et al., 2007). Instead,  $75 \pm 25$  nm PEGylated gold nanoparticles are reported to enter the  
fenestrated glomerular endothelia (80-100 nm pores) and accumulate in the kidney mesangium  
(Choi et al., 2011). Nanoparticle accumulation in the ovaries, clearly visible in the case of LNC  
(Fig. 4), is assumed to originate from fast growing and, thus, highly vascularized nature of the  
ovarian corpus luteum of mature female mice that leads to the EPR (enhanced permeability and  
275 retention) effect, described initially for tumours (Schädlich et al., 2012).

In our previous study, after i.v. injection, signals of fluorescent-labelled LNC 25 nm in the skin and  
in the intestine were found to be more intense than the corresponding signals of LNC 50/100 nm  
(Hirsjärvi et al., 2013). Thus, the results of the current study confirmed these findings. Almost twice  
280 the radioactivity of LNC 25 nm in carcass compared to LNC 50/100 nm at 1.5-4 h indicated,  
indeed, that the smallest LNC were distributed rapidly to the peripheral capillaries and probably  
perfused further to tissues increasing the skin fluorescence. Higher LNC 25 nm quantities in the  
intestine suggested more pronounced hepato-biliary evacuation. Differences in the elimination rate

of the three LNC could not be, however, revealed when estimated injected doses were compared to  
285 CPM of all organs. For each LNC type, differences between the different time points remained  
within 10% and were not significantly different.

Magnitude of the tumour accumulation of nanoparticles by the EPR effect together with a  
therapeutic effect (of an encapsulated drug) remains in general in the range of 3.5-12% (ID/g) (de  
290 Wolf et al., 2007; Kircheis et al., 2002; Kursa et al., 2002; Meng et al., 2011). Accumulation of  
LNC 25-100 nm in HEK293( $\beta_3$ ) tumour was a bit lower (1-3%). It should be noted, however, that  
this subcutaneous model is an “EPR-weak” tumour having well-structured, neo-angiogenic  
vasculature with tight endothelial junctions (Jin et al., 2007; Razkin et al., 2006).

295  $\gamma$ -Imaging of dual-labelled (radio+fluorescence) PEGylated polyacrylate nanoparticles revealed  
radioactivity in the cardiac area at early observation time points (5 min – 4 h) followed by  
increasing activity in liver and spleen up to 48 h (Yang et al., 2009). Tumour was poorly observable  
by  $\gamma$ -imaging but, instead, optical imaging that enhanced subcutaneous signal compared to deep  
signals, showed clear fluorescence staining in tumour. Subcutaneous tumours were well visualized  
300 by strongly surface-weighted optical imaging. Therefore, as in our studies ((Hirsjärvi et al., 2013)  
and the current study), optical imaging offers better resolution imaging especially for superficial  
organs whereas  $\gamma$ -scintigraphy recapitulates the global biodistribution of radiolabelled compounds  
in both internal and superficial organs.

305 To better compare the biodistribution of LNC measured by the two techniques, radioactivity and  
fluorescence intensity, the corresponding results were normalized by the value observed in the  
bone. The bone was selected because its radioactivity / fluorescence intensity level was observed to  
be settled in the middle of all analysed organs, allowing, thus, distinct representation of the data. In

order to quantify fluorescence intensity of dissected organs, graphical ROI estimation from images  
310 visualized by a fluorescent camera is commonly performed. (Goutayer et al., 2010; Kim et al.,  
2010; Na et al., 2011; Sancey et al., 2009; Schädlich et al., 2011a; Schädlich et al., 2011b; Yang et  
al., 2007). Alternatively, homogenization of each dissected organ followed by determination of the  
fluorescence intensity on a microtiter plate can be done (He et al., 2010; Meng et al., 2011). The  
fluorescence intensity technique (ROI drawing and estimation), compared to  $\gamma$ -counting,  
315 underestimated the LNC proportion in all the red and the dark red organs such as RES organs (liver,  
lung, spleen), and the kidney and adrenal. These organs are characterized by high blood perfusion.  
Similarly to our findings, *ex vivo* quantification of fluorescence intensity underestimated the uptake  
of polymer micelles in the liver, spleen, kidney, and also in the heart (Yang et al., 2007). For this  
reason, relative fluorescence intensity in other organs was found to be emphasized. Because of the  
320 fluorescence quantification technique in this study, intensities of thin organs (*i.e.* skin) were also  
slightly highlighted. It should be noted that direct comparison of the two quantification techniques  
after normalization (Fig. 4) is not recommendable but, instead, this approach revealed well the  
relative differences between the organs within each technique.

## 325 **5 Conclusions**

Biodistribution studies of radiolabelled  $^{99m}\text{Tc}$ -LNC in *nude* mice with subcutaneous HEK293( $\beta_3$ )  
xenografts revealed that the majority of the smallest studied particles (25 nm) disappeared quickly  
from the blood circulation within 1.5 h after the intravenous injection due to wider tissue  
330 distribution and faster elimination. Instead, 50 and 100 nm LNC remained in the circulation at least  
up to 4 h. At 24 h, biodistribution profiles of the all LNC were similar. Tumour accumulation of  
LNC in this EPR-weak tumour was low regardless the size. When biodistribution profiles of co-  
injected 50 nm fluorescent DiD-LNC and  $^{99m}\text{Tc}$ -LNC after animal sacrifice were compared,

underestimating tendency of fluorescence detection of LNC accumulation in highly-capturing and  
335 perfused organs (liver, adrenal, spleen, kidney, lung) was clearly observed but fluorescence  
detection allowed visualization of the tumour area. In following studies, we will further concentrate  
on the comparison of the two imaging / biodistribution evaluation techniques with the help of dual-  
labelled nanocarriers and different tumour models.

## 340 Acknowledgements

This work was financially supported by the French National Research Agency (ANR) in the frame  
of its programme in Nanosciences and Nanotechnologies (CALIF project no. ANR-08-NANO-006).

## 345 References

- Allard, E., Hindre, F., Passirani, C., Lemaire, L., Lepareur, N., Noiret, N., Menei, P., Benoit, J.P.,  
2008. Re-188-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for  
internal radiotherapy of malignant gliomas. *Eur J Nucl Med Mol Imag* 35, 1838-1846.
- 350 Baker, M., 2010. Whole-animal imaging: the whole picture. *Nature* 463, 977-980.
- Ballot, S., Noiret, N., Hindré, F., Denizot, B., Garin, E., Rajerison, H., Benoit, J.-P., 2006.  
 $^{99m}\text{Tc}/^{188}\text{Re}$ -labelled lipid nanocapsules as promising radiotracers for imaging and therapy:  
Formulation and biodistribution. *Eur J Nucl Med Mol Imag* 33, 602-607.
- Béduneau, A., Hindré, F., Clavreul, A., Leroux, J.-C., Saulnier, P., Benoit, J.-P., 2008. Brain  
355 targeting using novel lipid nanovectors. *J Control Release* 126, 44-49.
- Béduneau, A., Saulnier, P., Hindré, F., Clavreul, A., Leroux, J.-C., Benoit, J.-P., 2007. Design of  
targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments.  
*Biomaterials* 28, 4978-4990.
- Bourseau-Guilmain, E., Béjaud, J., Griveau, A., Lautram, N., Hindré, F., Weyland, M., Benoit, J.P.,  
360 Garcion, E., 2012. Development and characterization of immuno-nanocarriers targeting the  
cancer stem cell marker AC133. *Int J Pharm* 423, 93-101.
- Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano,  
M.R., Miyazono, K., Uesaka, M., Nishiyama, N., Kataoka, K., 2011. Accumulation of sub-  
100 nm polymeric micelles in poorly permeable tumours depends on size. *Nature*  
365 *Nanotechnol* 6, 815-823.
- Choi, C.H.J., Zuckerman, J.E., Webster, P., Davis, M.E., 2011. Targeting kidney mesangium by  
nanoparticles of defined size. *PNAS* 108, 6656-6661.
- Choi, H.S., Wenhao, L., Misra, P., Tanaka, E., Zimmer, J.P., Ipe, B.I., Bawendi, M.G., Frangioni,  
J.V., 2007. Renal clearance of quantum dots. *Nat Biotech* 25, 1165-1170.



- 370 Cirpanli, Y., Allard, E., Passirani, C., Bilensoy, E., Lemaire, L., Calis, S., Benoit, J.-P., 2011. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. *Int J Pharm* 403, 201-206.
- De Jong, W.H., Hagens, W.I., Krystek, P., Burger, M.C., Sips, A.J.A.M., Geertsma, R.E., 2008. Particle size-dependent organ distribution of gold nanoparticles after intravenous  
375 administration. *Biomaterials* 29, 1912-1919.
- de Wolf, H.K., Snel, C.J., Verbaan, F.J., Schiffelers, R.M., Hennink, W.E., Storm, G., 2007. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. *Int J Pharm* 331, 167-175.
- Dufort, S., Sancey, L., Wenk, C., Josserand, V., Coll, J.L., 2010. Optical small animal imaging in  
380 the drug discovery process. *Biochim Biophys Acta* 1798, 2266-2273.
- Farokhzad, O.C., Langer, R., 2009. Impact of nanotechnology on drug delivery. *ACS Nano* 3, 16-20.
- Garcion, E., Lamprecht, A., Heurtault, B., Paillard, A., Aubert-Pouessel, A., Denizot, B., Menei, P., Benoit, J.P., 2006. A new generation of anticancer, drug-loaded, colloidal vectors reverses  
385 multidrug resistance in glioma and reduces tumor progression in rats. *Mol Cancer Ther* 5, 1710-1722.
- Goutayer, M., Dufort, S., Josserand, V., Royère, A., Heinrich, E., Vinet, F., Bibette, J., Coll, J.-L., Texier, I., 2010. Tumor targeting of functionalized lipid nanoparticles: Assessment by in vivo fluorescence imaging. *Eur J Pharm Biopharm* 75, 137-147.
- 390 He, C., Hu, Y., Yin, L., Tang, C., Yin, C., 2010. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. *Biomaterials* 31, 3657-3666.
- Heurtault, B., Saulnier, P., Pech, B., Proust, J.-E., Benoit, J.-P., 2002. A novel phase inversion-based process for the preparation of lipid nanocarriers. *Pharm Res* 19, 875-880.
- Heurtault, B., Saulnier, P., Pech, B., Venier-Julienne, M.-C., Proust, J.-E., Phan-Tan-Luu, R.,  
395 Benoit, J.-P., 2003. The influence of lipid nanocapsule composition on their size distribution. *Eur J Pharm Sci* 18, 55-61.
- Hirn, S., Semmler-Behnke, M., Schleh, C., Wenk, A., Lipka, J., Schäffler, M., Takenaka, S., Möller, W., Schmid, G., Simon, U., Kreyling, W.G., 2011. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous  
400 administration. *Eur J Pharm Biopharm* 77, 407-416.
- Hirsjärvi, S., Dufort, S., Gravier, J., Texier, I., Qiao, Y., Bibette, J., Sancey, L., Josserand, V., Passirani, C., Benoit, J.-P., Coll, J.-L., 2013. Influence of size, surface coating and fine chemical composition on the *in vitro* reactivity and *in vivo* biodistribution of lipid nanocapsules *versus* lipid nanoemulsions in cancer models. *Nanomedicine: NBM* 9, 375-  
405 387.
- Hirsjärvi, S., Passirani, C., Benoit, J.-P., 2011. Passive and active tumour targeting with nanocarriers. *Curr Drug Discov Technol* 8, 188-196.
- Hoarau, D., Delmas, P., David, S., Roux, E., Leroux, J.-C., 2004. Novel long-circulating lipid nanocapsules. *Pharm Res* 21, 1783-1789.
- 410 Jin, Z.-H., Josserand, V., Foillard, S., Boturyn, D., Dumy, P., Favrot, M.-C., Coll, J.-L., 2007. *In vivo* optical imaging of integrin  $\alpha_v\beta_3$  in mice using multivalent or monovalent cRGD targeting vectors. *Mol Cancer* 6, 41.
- Kim, J.-Y., Choi, W.I., Kim, Y.H., Tae, G., Lee, S.-Y., Kim, K., Kwon, I.C., 2010. *In-vivo* tumor targeting of pluronic-based nano-carriers. *J Control Release* 147, 109-117.
- 415 Kircheis, R., Ostermann, E., Wolschek, M.F., Lichtenberger, C., Magin-Lachmann, C., Wightman, L., Kurs, M., Wagner, E., 2002. Tumor-targeted gene delivery of tumor necrosis factor- $\alpha$  induces tumor necrosis and tumor regression without systemic toxicity. *Cancer Gene Ther* 9, 673-680.

- Kumari, A., Yadav, S.K., Yadav, S.C., 2010. Biodegradable polymeric nanoparticles based drug  
420 delivery systems. *Colloid Surf B* 75, 1-18.
- Kursa, M., Walker, G.F., Roessler, V., Ogris, M., Roedl, W., Kircheis, R., Wagner, E., 2002. Novel  
shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic  
tumor-targeted gene transfer. *Bioconjugate Chem* 14, 222-231.
- Lacoeuille, F., Hindré, F., Moal, F., Roux, J., Passirani, C., Couturier, O., Cales, P., Le Jeune, J.J.,  
425 Lamprecht, A., Benoit, J.P., 2007. In vivo evaluation of lipid nanocapsules as a promising  
colloidal carrier for paclitaxel. *Int J Pharm* 344, 143-149.
- Lamprecht, A., Saumet, J.-L., Roux, J., Benoit, J.-P., 2004. Lipid nanocarriers as drug delivery  
system for ibuprofen in pain treatment. *Int J Pharm* 278, 407-414.
- Lee, H., Fonge, H., Hoang, B., Reilly, R.M., Allen, C., 2010. The effects of particle size and  
430 molecular targeting on the intratumoral and subcellular distribution of polymeric  
nanoparticles. *Mol Pharm* 7, 1195-1208.
- Meng, H., Xue, M., Xia, T., Ji, Z., Tarn, D.Y., Zink, J.I., Nel, A.E., 2011. Use of size and a  
copolymer design feature to improve the biodistribution and the enhanced permeability and  
retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft  
435 tumor model. *ACS Nano* 5, 4131-4144.
- Mévellec, F., Tisato, F., Refosco, F., Roucoux, A., Noiret, N., Patin, H., Bandoli, G., 2002.  
Synthesis and characterization of the "sulfur-rich" bis (perthiobenzoato) (dithiobenzoato)  
technetium (III) heterocomplex. *Inorg Chem* 41, 598-601.
- Morille, M., Montier, T., Legras, P., Carmoy, N., Brodin, P., Pitard, B., Benoit, J.-P., Passirani, C.,  
440 2010. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting.  
*Biomaterials* 31, 321-329.
- Morille, M., Passirani, C., Dufort, S., Bastiat, G., Pitard, B., Coll, J.-L., Benoit, J.-P., 2011. Tumor  
transfection after systemic injection of DNA lipid nanocapsules. *Biomaterials* 32, 2327-  
2333.
- Müller, R.H., Shegokar, R., Keck, C.M., 2011. 20 years of lipid nanoparticles (SLN & NLC):  
445 present state of development & industrial applications. *Curr Drug Discov Technol* 8, 207-  
227.
- Na, J.H., Koo, H., Lee, S., Min, K.H., Park, K., Yoo, H., Lee, S.H., Park, J.H., Kwon, I.C., Jeong,  
S.Y., Kim, K., 2011. Real-time and non-invasive optical imaging of tumor-targeting glycol  
450 chitosan nanoparticles in various tumor models. *Biomaterials* 32, 5252-5261.
- Paillard, A., Hindré, F., Vignes-Colombeix, C., Benoit, J.-P., Garcion, E., 2010. The importance of  
endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability.  
*Biomaterials* 31, 7542-7554.
- Peltier, S., Oger, J.-M., Lagarce, F., Couet, W., Benoit, J.-P., 2006. Enhanced oral paclitaxel  
455 bioavailability after administration of paclitaxel-loaded lipid nanocapsules. *Pharm Res* 23,  
1243-1250.
- Perrault, S.D., Walkey, C., Jennings, T., Fischer, H.C., Chan, W.C.W., 2009. Mediating tumor  
targeting efficiency of nanoparticles through design. *Nano Lett* 9, 1909-1915.
- Razkin, J., Josserand, V., Boturnyn, D., Jin, Z.-h., Dumy, P., Favrot, M., Coll, J.-L., Texier, I., 2006.  
460 Activatable fluorescent probes for tumour-targeting imaging in live mice. *ChemMedChem*  
1, 1069-1072.
- Sancey, L., Dufort, S., Josserand, V., Keramidas, M., Righini, C., Rome, C., Faure, A.C., Foillard,  
S., Roux, S., Boturnyn, D., Tillement, O., Koenig, A., Boutet, J., Rizo, P., Dumy, P., Coll,  
J.L., 2009. Drug development in oncology assisted by noninvasive optical imaging. *Int J*  
465 *Pharm* 379, 309-316.
- Schädlich, A., Caysa, H., Mueller, T., Tenambergen, F., Rose, C., Göpferich, A., Kuntsche, J.,  
Mäder, K., 2011a. Tumor accumulation of NIR fluorescent PEG-PLA nanoparticles: impact  
of particle size and human xenograft tumor model. *ACS Nano* 5, 8710-8720.

- Schädlich, A., Hoffmann, S., Mueller, T., Caysa, H., Rose, C., Göpferich, A., Li, J., Kuntsche, J.,  
 470 Mäder, K., 2012. Accumulation of nanocarriers in the ovary: a neglected toxicity risk? J  
 Control Release 160, 105-112.
- Schädlich, A., Rose, C., Kuntsche, J., Caysa, H., Mueller, T., Göpferich, A., Mäder, K., 2011b.  
 How stealthy are PEG-PLA nanoparticles? An NIR *in vivo* study combined with detailed  
 size measurements. Pharm Res 28, 1995-2007.
- 475 Sonavane, G., Tomoda, K., Makino, K., 2008. Biodistribution of colloidal gold nanoparticles after  
 intravenous administration: effect of particle size. Colloid Surf B 66, 274-280.
- Sun, X., Rossin, R., Turner, J.L., Becker, M.L., Joralemon, M.J., Welch, M.J., Wooley, K.L., 2005.  
 An assessment of the effects of shell cross-linked nanoparticle size, core composition, and  
 surface PEGylation on *in vivo* biodistribution. Biomacromolecules 6, 2541-2554.
- 480 Torchilin, V., 2007. Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res 24, 1-16.
- Torchilin, V.P., 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug  
 Discov 4, 145-160.
- Vanpouille-Box, C., Lacoeyille, F., Belloche, C., Lepareur, N., Lemaire, L., LeJeune, J.-J., Benoit,  
 J.-P., Menei, P., Couturier, O.F., Garcion, E., Hindré, F., 2011a. Tumor eradication in rat  
 485 glioma and bypass of immunosuppressive barriers using internal radiation with 188Re-lipid  
 nanocapsules. Biomaterials 32, 6781-6790.
- Vanpouille-Box, C., Lacoeyille, F., Roux, J., Aubé, C., Garcion, E., Lepareur, N., Oberti, F.,  
 Bouchet, F., Noiret, N., Garin, E., Benoit, J.-P., Couturier, O., Hindré, F., 2011b. Lipid  
 nanocapsules loaded with rhenium-188 reduce tumor progression in a rat hepatocellular  
 490 carcinoma model. PLoS ONE 6, e16926.
- Weyland, M., Manero, F., Paillard, A., Grée, D., Viault, G., Jarnet, D., Menei, P., Juin, P., Chourpa,  
 I., Benoit, J.P., Grée, R., Garcion, E., 2011. Mitochondrial targeting by use of lipid  
 nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1.  
 J Control Release 151, 74-82.
- 495 Vonarbourg, A., Passirani, C., Saulnier, P., Benoit, J.-P., 2006. Parameters influencing the  
 stealthiness of colloidal drug delivery systems. Biomaterials 27, 4356-4373.
- Vonarbourg, A., Saulnier, P., Passirani, C., Benoit, J.-P., 2005. Electrokinetic properties of  
 noncharged lipid nanocapsules: Influence of the dipolar distribution at the interface.  
 Electrophoresis 26, 2066-2075.
- 500 Yang, Z., Leon, J., Martin, M., Harder, J.W., Zhang, R., Liang, D., Lu, W., Tian, M., Gelovani,  
 J.G., Qiao, A., Li, C., 2009. Pharmacokinetics and biodistribution of near-infrared  
 fluorescence polymeric nanoparticles. Nanotechnol 20, 165101.
- Yang, Z., Zheng, S., Harrison, W.J., Harder, J., Wen, X., Gelovani, J.G., Qiao, A., Li, C., 2007.  
 Long-circulating near-infrared fluorescence core-cross-linked polymeric micelles: synthesis,  
 505 characterization, and dual nuclear/optical imaging. Biomacromolecules 8, 3422-3428.
- Zou, J., Saulnier, P., Perrier, T., Zhang, Y., Manninen, T., Toppila, E., Pyykkö, I., 2008.  
 Distribution of lipid nanocapsules in different cochlear cell populations after round window  
 membrane permeation. J Biomed Mat Res B 87B, 10-18.

510

## Figure captions


Table 1. Compositions of LNC of different sizes.

	Solutol® (mg)	Lipoid® (mg)	Labrafac® (mg)	NaCl (mg)	Water (mg)	Concentration (mg/mL)
LNC 25 nm	645	25	282	30	685	168
LNC 50 nm	282	25	343	30	987	115
LNC 100 nm	161	25	403	30	1048	104


515

Table 2. Size and  $\zeta$ -potential of  $^{99m}\text{Tc}$ -LNC measured in physiological PBS.

	Diameter (nm)	PdI	$\zeta$ -Potential (mV)
LNC 25 nm	25±2	0.08	-3±1
LNC 50 nm	51±1	0.03	-4±1
LNC 100 nm	93±1	0.04	-6±1



520 Figure 1. Biodistribution of 25, 50, and 100 nm <sup>99m</sup>Tc-LNC in different organs 1.5 h, 4 h, and 24 h after intravenous injection. CPM = counts per minute



525 Figure 2.  $\gamma$ -Scintigraphic images expressing biodistribution of 25, 50, and 100 nm  $^{99m}\text{Tc}$ -LNC in mice 1.5 h, 3 h, 5 h, and 24 h after intravenous injection. Arrows indicate the liver.

530





Figure 3. LNC biodistribution by optical imaging. Fluorescence images of a mouse 24 h after an i.v. injection of a 50%-50% mixture of 50 nm  $^{99m}\text{Tc}$ -LNC and 50 nm DiD-LNC. Mouse lying on its back (A, arrow indicates the liver) and belly (B, arrow indicates the tumour).



535

540

Figure 4. Comparison of the two detection techniques, radioactivity and fluorescence intensity, for quantification of organ distribution of the 50%-50% mixture (50 nm DiD-LNC and  $^{99m}\text{Tc}$ -LNC) 24 h after injection (A). Example of the dissected organs visualized by a fluorescence camera (B).